

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 52ND ASCO ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that a series of abstracts highlighting new study results on Halaven® (eribulin mesylate; halichondrin class microtubule dynamics inhibitor, “eribulin”) and Lenvima® (lenvatinib mesylate; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, “lenvatinib”) will be presented during the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from June 3 to 7, 2016.

Poster presentations for this year’s ASCO meeting include a presentation highlighting the results of a Phase I clinical study of eribulin liposomal formulation in solid tumors. Presentations for lenvatinib include updated results from the SELECT study regarding response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer as well as final analysis results of a Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

Major Poster Presentations:

Product	Abstract title and scheduled presentation date and time (local time)
Eribulin (Halaven) Abstract No: 2524	Phase 1 multicenter, open-label study to establish the maximum tolerated dose (MTD) of two administration schedules of E7389 (eribulin) liposomal formulation in patients (pts) with solid tumors. Poster Presentation June 5 (Sun), 08:00-11:30
Eribulin (Halaven) Abstract No: 11015	Evaluation of quality of life at progression in patients with soft tissue sarcoma. Poster Presentation June 6 (Mon), 08:00-11:30
Eribulin (Halaven) Abstract No: 11037	Subtype-specific activity in liposarcoma (LPS) patients (pts) from a phase 3, open-label, randomized study of eribulin (ERI) versus dacarbazine (DTIC) in pts with advanced LPS and leiomyosarcoma (LMS). Poster Presentation June 6 (Mon), 08:00-11:30

(continued on following page)

Lenvatinib (Lenvima) Abstract No: 4553	Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC). Poster Presentation June 6 (Mon), 13:00-16:30
Lenvatinib (Lenvima) Abstract No: 6088	Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results. Poster Presentation June 4 (Sat), 13:00-16:30
Lenvatinib (Lenvima) Abstract No: 6089	Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC): Updated results from SELECT. Poster Presentation June 4 (Sat), 13:00-16:30

(Note) SELECT Study: Study of E7080 "LEnvatinib" in Differentiated Cancer of the Thyroid

Media Inquiries:

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120